GLP-1 Receptor Agonists: A New Treatment in Parkinson's Disease.
Kallirhoe KalinderiVasileios PapaliagkasLiana FidaniPublished in: International journal of molecular sciences (2024)
Parkinson's disease (PD) is one of the most common neurodegenerative diseases. Recent data highlight similarities between neurodegenerative diseases, including PD and type 2 diabetes mellitus (T2DM), suggesting a crucial interplay between the gut-brain axis. Glucagon-like peptide-1 receptor (GLP-1R) agonists, known for their use in T2DM treatment, are currently extensively studied as novel PD modifying agents. For this narrative review article, we searched PubMed and Scopus databases for peer-reviewed research, review articles and clinical trials regarding GLP-1R agonists and PD published in the English language with no time restrictions. We also screened the references of the selected articles for possible additional articles in order to include most of the key recent evidence. Many data on animal models and preclinical studies show that GLP1-R agonists can restore dopamine levels, inhibit dopaminergic loss, attenuate neuronal degeneration and alleviate motor and non-motor features of PD. Evidence from clinical studies is also very promising, enhancing the possibility of adding GLP1-R agonists to the current armamentarium of drugs available for PD treatment.
Keyphrases
- clinical trial
- big data
- randomized controlled trial
- stem cells
- autism spectrum disorder
- type diabetes
- cardiovascular disease
- systematic review
- metabolic syndrome
- multiple sclerosis
- white matter
- combination therapy
- machine learning
- mesenchymal stem cells
- brain injury
- adipose tissue
- resting state
- functional connectivity
- cerebral ischemia
- phase ii
- subarachnoid hemorrhage
- cell therapy
- double blind